PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2008
CASE
AUTH/2164/9/08 Takeda

AUTH/2164/9/08: MSD v Takeda – Actos/Competact ad implied CV event reduction and misused β€œindependent”

A pioglitazone journal ad implied CV event reduction as part of the product’s benefits and called a Takeda-funded meta-analysis β€œindependent”. Breaches of…

2008
CASE
AUTH/2173/10/08 Syner-Med

AUTH/2173/10/08: Nurse v Syner-Med – Ferinject detail aid and misleading administration information

A nurse challenged a Ferinject detail aid as inaccurate. The PMCPA found the CosmoFer administration chart and a β€œSingle dose delivery” claim…

2009
CASE
AUTH/2270/10/09 Merz Pharma UK ⭐ Case of the Week

AUTH/2270/10/09: Allergan v Merz Pharma β€” β€œAt least as effective as Botox” claim based on non-inferiority studies

Merz’s exhibition claim that Xeomin was β€œat least as effective as Botox” was ruled misleading because the cited studies were non-inferiority trials…

2009
CASE
AUTH/2252/7/09 CV Therapeutics

AUTH/2252/7/09: Professor v CV Therapeutics Europe (Ranexa) – memory stick seen as inducement to secure an interview

A professor said a rep refused to leave a Ranexa memory stick unless she saw him, creating an impression of inducement. Breach…

2009
CASE
AUTH/2232/5/09 Cephalon

Cephalon: Uncertified Effentora launch training materials and inadequate representative training (AUTH/2232/5/09)

Former rep alleged poor Code training and uncertified Effentora launch materials. PMCPA found breaches for uncertified briefing materials and inadequate/undocumented training, but…

2009
CASE
AUTH/2285/12/09 Beacon Pharmaceuticals

AUTH/2285/12/09: Consultant Neurologist v Beacon (Episenta letters) – No breach (Clause 7.2)

Beacon’s mailing claimed Episenta was bioequivalent to and interchangeable with Epilim Chrono. A neurologist said this conflicted with epilepsy guidance on avoiding…

2009
CASE
AUTH/2290/12/09 Astellas Pharma

Astellas Mycamine advisory boards ruled disguised promotion and inducement (AUTH/2290/12/09)

Anonymous clinician alleged Mycamine advisory boards were promotional and attendees were profiled for follow-up. PMCPA found disguised promotion, inducement via fees, and…

2010
CASE
AUTH/2316/5/10 Flynn Pharma ⭐ Case of the Week

Flynn Pharma: competitor disparagement in rep training and discussion about Abstral during Actiq promotion (AUTH/2316/5/10)

A palliative medicine consultant complained about an Actiq rep’s comments on competitor Abstral. The Panel found misleading/disparaging competitor messaging and inadequate training…

2010
CASE
AUTH/2294/1/10 AstraZeneca

AstraZeneca: Seroquel ad claim of β€œfavourable weight profile” ruled misleading (AUTH/2294/1/10, AUTH/2296/1/10, AUTH/2297/1/10)

PMCPA ruled a UK journal ad for Seroquel misleading for implying an advantage on weight gain (β€œfavourable weight profile across the full…

2010
CASE
AUTH/2331/7/10 Eli Lilly

Novo Nordisk v Lilly: Byetta promotional meeting linked to pre-diabetes discussion (AUTH/2331/7/10)

A Byetta-branded promotional meeting included a pre-diabetes presentation. PMCPA ruled this created an inevitable association with Byetta and implied off-licence use, breaching…

2009
CASE
AUTH/2234/5/09 Novo Nordisk

AUTH/2234/5/09: Novo Nordisk ruled in breach for repeated pre-licence promotion of Victoza (liraglutide) via website, journal insert and meetings

Novo Nordisk was found in breach for promoting unlicensed liraglutide (Victoza) before UK authorisation via an β€œeducational” website, a paid journal insert…

2015
CASE
Otsuka

Employee complaint: Otsuka Europe/Otsuka UK delays updating SPCs, eMC and prescribing information (Jinarc, Samsca, Abilify)

Employee alleged weak processes meant SPC/prescribing info updates weren’t communicated/implemented promptly. Panel found multiple breaches (Clauses 2, 4.1, 9.1) and governance failures;…

2019
CASE
AUTH/3171/3/19 Novartis Pharmaceuticals UK ⭐ Case of the Week

AUTH/3171/3/19: Health professional v Novartis β€” meeting attendance certificate (no breach)

A health professional alleged a rep used delivery of an attendance certificate to secure a follow-up meeting (Clause 15.3). The Panel found…

2018
CASE
AUTH/3112/11/18 Eli Lilly

Lilly rheumatology website: β€œshare by email” templates breached high standards (AUTH/3112/11/18)

Complaint about Lilly’s rheumatology HCP website. Most allegations not upheld, but β€œshare by email” templates didn’t make Lilly’s involvement clear to recipients,…

2019
CASE
AUTH/3159/2/19 Vifor Pharma

AUTH/3159/2/19: Pharmacosmos v Vifor – proactive β€œpeer-to-peer” call ruled disguised promotion and uncertified use of publication

Vifor’s CMO proactively discussed a comparative safety paper with UK HCPs. One call was ruled disguised promotion and the paper should have…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training